Princeton Global Asset Management LLC Purchases 3,022 Shares of Eli Lilly and Company $LLY

Key Points

• Princeton Global Asset Management more than doubled its stake in Eli Lilly during the first quarter, buying an additional 3,022 shares and bringing its total holdings to 5,875 shares worth about $5.4 million.
• Eli Lilly continues to attract heavy institutional interest, with about 82.5% of shares owned by hedge funds and other institutions, while several other funds also increased their positions recently.
• The company posted strong quarterly results, beating earnings and revenue estimates, and also raised its full-year guidance; analysts currently rate the stock a Moderate Buy with a consensus price target of about $1,235.

Princeton Global Asset Management LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 105.9% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,875 shares of the company's stock after buying an additional 3,022 shares during the period. Princeton Global Asset Management LLC's holdings in Eli Lilly and Company were worth $5,404,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Spire Wealth Management grew its stake in Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company's stock valued at $29,789,000 after buying an additional 592 shares in the last quarter. Coldstream Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock worth $32,365,000 after acquiring an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company's stock worth $33,471,000 after acquiring an additional 7,338 shares during the period. Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Eli Lilly and Company by 3.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company's stock worth $126,022,000 after acquiring an additional 5,595 shares during the period. Finally, Stonebridge Capital Advisors LLC grew its position in shares of Eli Lilly and Company by 318.1% in the third quarter. Stonebridge Capital Advisors LLC now owns 10,519 shares of the company's stock valued at $8,026,000 after purchasing an additional 8,003 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,226.22 on Tuesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,238.00. The business has a 50-day simple moving average of $1,042.73 and a 200 day simple moving average of $1,022.85. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.15 trillion, a price-to-earnings ratio of 43.56, a PEG ratio of 1.32 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company's revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 24.58%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Monday, June 22nd. Barclays lifted their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a report on Monday, May 4th. HSBC cut Eli Lilly and Company from a "hold" rating to a "reduce" rating and decreased their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Rothschild & Co Redburn increased their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Finally, Bank of America raised their price objective on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a "buy" rating in a research report on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,235.07.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA selected Eli Lilly for its new PreCheck pilot program, which is designed to speed review of new U.S. manufacturing facilities. That matters because Lilly is spending $27 billion to build four plants, so faster approvals could support capacity expansion and future drug supply. Article Title
• Positive Sentiment: Lilly’s Jaypirca received a positive opinion from Europe’s CHMP for chronic lymphocytic leukemia, improving the odds of broader European approval and potentially expanding the drug’s commercial opportunity. Article Title
• Positive Sentiment: The stock hit a new all-time high and 52-week high as investors reacted to recent pipeline progress, including positive Jaypirca data and expanded Medicare access for Zepbound and other obesity treatments, which boosts the outlook for Lilly’s growth franchises. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.